Proof-dependent guidelines issued in 2014 because of the American Academy of Neurology concluded that nabiximols might be effective for bettering subjective spasticity indicators, almost certainly ineffective for lowering goal spasticity measures or bladder incontinence, And perhaps ineffective for cutting down multiple sclerosis–relevant tremor.